Background-Elderly patients are more sensitive than younger patients to myocardial ischemia, which results in higher mortality. We investigated how aging affects the cardioprotective AMP-activated protein kinase (AMPK) signaling pathway. Methods and Results-Ischemic AMPK activation was impaired in aged compared with young murine hearts. The expression and secretion of the AMPK upstream regulator, macrophage migration inhibitory factor (MIF), were lower in aged compared with young adult hearts. Additionally, the levels of hypoxia-inducible factor 1␣, a known transcriptional activator of MIF, were reduced in aged compared with young hearts. Ischemia-induced AMPK activation in MIF knockout mice was blunted, leading to greater contractile dysfunction in MIF-deficient than in wild-type hearts. Furthermore, intramyocardial injection of adenovirus encoding MIF in aged mice increased MIF expression and ischemic AMPK activation and reduced infarct size. Conclusions-An impaired MIF-AMPK activation response in senescence thus may be attributed to an agingassociated defect in hypoxia-inducible factor 1␣, the transcription factor for MIF. In the clinical setting, impaired cardiac hypoxia-inducible factor 1␣ activation and consequent reduced MIF expression may play an important role in the increased susceptibility to myocardial ischemia observed in older cardiac patients. (Circulation. 2010;122: 282-292.)
olism during low-flow I/R and limits ischemic injury and apoptosis during postischemic reperfusion. 18 We also reported that macrophage migration inhibitory factor (MIF) modulates the activation of AMPK during ischemia, and we suggested that genetic variation in the expression of MIF, which is encoded in a functionally polymorphic locus, 19 may affect the responsiveness of the human heart to ischemia via the AMPK pathway. 20 In the present report, we sought to examine whether AMPK activity is reduced in the senescent heart and whether such a reduction contributes to increased ischemia injury with aging.
Methods

In Vivo Regional Ischemia and Experimental Myocardial Infarction
Mice were anesthetized and placed on a ventilator (Harvard Rodent Ventilator, Harvard Apparatus, Holliston, Mass), 20 and core temperature was maintained at 37°C with a heating pad. After left lateral thoracotomy, the left anterior descending artery was occluded for different time periods. The hearts were then rapidly excised, and the ischemic region of the left ventricle (LV) was freeze-clamped in liquid nitrogen 21 for biochemical analysis. The left anterior descending artery was occluded for 20 minutes with an 8 -0 nylon suture and polyethylene tubing to prevent arterial injury and then reperfused for 4 hours. ECGs confirmed ischemic repolarization changes (ST-segment elevation) during coronary occlusion (ADInstruments Inc, Colorado Springs, Colo). The hearts were then excised, perfusion fixed, and stained to delineate the extent of myocardial necrosis as a percent of nonperfused ischemic area at risk. 20 Viable tissue in the ischemic region was stained red by 2,3,5-triphenyltetrazolium, and the nonischemic region was stained blue with Evans blue dye. Hearts were fixed, sectioned, photographed with a Leica microscope, and analyzed with National Institutes of Health Image software.
Supplemental Methodology
For a detailed explanation of methods relative to echocardiographic assessment, AMPK activity analysis, 20 heart perfusion Intolerance of aged hearts during I/R. A, Hearts were subjected to in vivo regional I/R (20 minutes/4 hours) and dual staining to assess the extent of myocardial necrosis (top). Bars represent the percent of ischemic area at risk in young, aged, and young AMPK KD hearts (bottom). Values are meanϮSEM; nϭ4 to 5 per group. *PϽ0.05 vs young; †Pϭ0.02 vs aged. B, Young and aged hearts were subjected to ex vivo I/R (20 minutes/30 minutes), and heart rate-LV pressure product was assessed. Values are meanϮSEM; nϭ4 per group. *Pϭ0.006 vs young. and cardiac functions, 18 immunoblotting, 21 real-time reversetranscriptase polymerase chain reaction, 22 high-energy phosphate and glycogen measurement, 23, 24 MIF secretion analysis, 20 measurement of isolated cardiomyocytes contractile function, 23 and MIF adenovirus delivery, 25 please see the Method section of the online-only Data Supplement.
Statistical Analysis
Data are expressed as meanϮSEM. A variety of statistical tests using SAS software (version 9.2, SAS Institute Inc, Cary, NC) were used on the basis of the design required for the specific question being asked (number of age groups times number of treatments). This meant using t tests and repeated-and non- repeated-measures 1-way and 2-way ANOVA. For the singlefactorial and multifactorial analyses in which a significant overall F value was obtained, indicating significant main and/or interaction effects, the appropriate posthoc test(s) were performed to measure individual group differences of interest. A value of PϽ0.05 was considered statistically significant.
Results
Cardiac Phenotype of Young and Aged Mice
Echocardiographic studies were performed to examine hearts with respect to in vivo LV function. The heart rate (HR), LV end-systolic and end-diastolic dimensions, and percent fractional shortening were similar and in the normal range for both young and aged mice under a basal physiological state (Table I of the online-only Data Supplement).
Impaired Ischemic Activation of AMPK in the Aged Heart
We compared AMPK signaling in hearts from young adult (4 to 6 months) and aged (24 to 26 months) mice during in vivo regional ischemia. Ischemia stimulated the phosphorylation of AMPK at Thr 172 of the catalytic ␣ subunit ( Figure 1A ), and the activity of AMPK␣1 and ␣2 ( Figure 1B ) was decreased in aged hearts compared with their younger counterparts. These results suggest that the AMPK responsiveness to ischemia is reduced in the aged heart. 
Aged Hearts Demonstrate Intolerance to Ischemic Injury
Mounting evidence supports a beneficial effect of AMPK in limiting cardiac damage during I/R. 18, 26, 27 We next compared myocardial infarct size in response to in vivo regional I/R in young and aged hearts. After 20 minutes of coronary artery ligation and 4 hours of reperfusion, the myocardial infarct in aged hearts was significantly larger than in young hearts ( Figure  2A ). To confirm that reduced AMPK activation was associated with intolerance to ischemic injury during aging, we compared the response to ischemic stress of young AMPK-kinase dead (KD) 18 transgenic mouse hearts with that of wild-type (WT) littermates. Notably, the myocardial infarct was significantly larger in AMPK KD hearts than in WT littermate hearts ( Figure   Figure 5 . Impaired AMPK signaling in MIF KO and MIF receptor (CD74) KO hearts. A, MIF KO and CD74 KO and WT mice were subjected to in vivo regional ischemia by left anterior descending artery occlusion for 10, 20, or 30 minutes to determine the degree of ischemic AMPK activation (top). Bars represent the relative levels of phosphorylated (p-) AMPK (bottom); nϭ6 per group. *PϽ0.01 vs control; †PϽ0.05 vs WT ischemia. B, Heart rate-LV pressure product of isolated WT, MIF KO, and CD74 KO hearts; nϭ4 per group. *PϽ0.05 (both MIF KO and CD74 KO) vs WT. C and D, The kinetics of AMPK phosphorylation induced by hypoxia in WT, MIF KO, and CD74 KO cardiomyocytes; nϭ6 per group. *PϽ0.05 vs control; †PϽ0.05 vs WT hypoxia. E, Heart rate-LV pressure product of isolated young and aged WT hearts and young and aged MIF KO hearts; nϭ4 per group. *PϽ0.05 vs young WT. 2A). However, there was a significant difference in infarct size between the aged WT and young AMPK KD hearts (Figure 2A ). Aged hearts also demonstrated impaired recovery of postischemic LV rate-pressure product in the setting of ischemia and reperfusion, whereas this contractility index was similar to young hearts at baseline ( Figure 2B ). After 20 minutes of ischemia and 30 minutes of postischemic reperfusion, the recovery of function in the aged hearts was more noticeably impaired during postischemic reperfusion, as evidenced by the reduced heart rate-LV pressure product, indicating diminished LV contractility during reperfusion in aged versus young hearts ( Figure 2B ).
Resveratrol Activation of AMPK Attenuates Ischemic Injury in the Aged Heart
We next compared the effect of an AMPK activator, resveratrol, 28,29 on both young and aged hearts during ischemia. Pretreatment with 20 minutes of resveratrol (10 mol/L) followed by 20 minutes of global ischemia increased ischemia-stimulated AMPK and acetyl-CoA carboxylase phosphorylation in both young and aged hearts ( Figure 3A and 3B). Resveratrol treatment decreased myocardial infarct size in aged hearts ( Figure 3C ) and improved recovery of function in aged hearts during the postischemic reperfusion period, as evidenced by the significantly elevated heart rate-LV pressure product (Figure 3D) . No differences in ex vivo heart rate were noted between the 2 age groups (data not shown).
Downregulation of MIF Expression and Secretion in the Aged Heart
MIF modulates the activation of cardiac AMPK, which plays an important role in mitigating cardiac damage caused by I/R. 20 To determine whether a blunted ischemic AMPK activation was due to MIF deficiency in senescence, we examined the expression levels of MIF in both young and aged hearts. The results demonstrated that both messenger RNA expression and protein expression of cardiac MIF were markedly decreased in the aged compared with young nonperfused hearts ( Figure 4A and 4B), supporting our hypothesis of an aging-associated reduction of MIF, an upstream factor in ischemia-induced AMPK activation, in the heart. We further examined whether cardiac MIF secretion is decreased in the aged heart. We studied the isolated mouse heart perfused with crystalloid buffer, thereby eliminating the potential contribution of MIF from circulating cells. Ischemia-triggered cardiac MIF release was attenuated in senescence ( Figure  4C ). Furthermore, we observed no change in activities of the upstream AMPK-activating kinases LKB1 and Ca 2ϩ / calmodulin-dependent protein kinase kinase ␤ in young and aged hearts ( Figure I of the online-only Data Supplement).
To ascertain potential mechanisms for the downregulation of MIF in the aged hearts, we examined the transcriptional factor, hypoxia-inducible factor 1␣ (HIF-1␣), which regulates MIF expression. 30 As shown in Figure 4D , HIF-1␣ protein levels were significantly reduced in aged hearts compared with young hearts. Although HIF-1␣ levels were upregulated by ischemia in both groups, the magnitude of HIF-1␣ induced by ischemia in aged hearts was significantly lower than in young hearts. The HIF-1␣ inhibitor YC-1 31 (10 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 IP for 3 days) depressed cardiac HIF-1␣ levels, decreased MIF expression in young adult hearts ( Figure 4E) , and downregulated the expression of MIF messenger RNA in cardiomyocytes ( Figure 4F ). The treatment of young hearts with YC-1 also blunted ischemic AMPK activation ( Figure 4G ) and resulted in larger myocardial infarcts than in untreated controls ( Figure 4H) ; the infracted area was even larger than that seen in aged control hearts. Notably, YC-1 treatment reduced ischemia-triggered MIF secretion of young hearts but did not affect the baseline MIF secretion ( Figure 4I ).
D, Peak shortening (PS; normalized to cell length). E, Maximal velocity of shortening (ϩdL/dt). F, Relengthening (ϪdL/dt). G, Time to peak shortening (TPS). H, Time to 90% relengthening (TR 90
)
Impaired AMPK Activation of MIF Knockout Hearts/Cardiomyocytes in Response to Ischemia/Hypoxia
To verify the permissive role of MIF as a mediator of ischemic AMPK activation, in vivo regional ischemia was performed by left anterior descending artery occlusion (10, 20, or 30 minutes) in MIF knockout (KO) and WT mice. The results demonstrated that AMPK activation was markedly reduced in MIF KO versus WT hearts ( Figure 5A ). Moreover, ischemic activation of AMPK also was reduced in the MIF receptor, CD74-deficient heart ( Figure 5A ). The MIF KO and CD74 KO hearts also demonstrated significantly impaired recovery of postischemic LV contractile function in the setting of ischemia and reperfusion ( Figure 5B ). We next measured the response of isolated cardiomyocytes from WT, MIF KO, or CD74 KO hearts to 10, 20, or 30 minutes of hypoxia treatment; the data showed that hypoxia stimulated AMPK phosphorylation of cardiomyocytes in a time-dependent manner and that the hypoxic AMPK activation of MIF KO and CD74 KO cardiomyocytes was significantly impaired compared with WT cardiomyocytes ( Figure 5C and 5D ). MIF KO 20 and CD74 KO mice nevertheless demonstrated a normal baseline cardiac phenotype with respect to LV size and function (Table II of the online-only Data Supplement). Notably, there is no significant difference in ischemic tolerance between young and aged MIF KO hearts ( Figure 5E ), indicating that aging-associated decline in MIF expression is an important factor for ischemic intolerance in the aged heart.
We next compared the response to hypoxia of isolated cardiomyocytes from aged hearts with those from young †Pϭ0.01 vs aged. B, Percent of infarct size to area at risk of isolated young, aged, and AMPK KD hearts subjected to ex vivo global I/R (20 minutes/2 hours); nϭ4 per group. *PϽ0.05 vs young; †Pϭ0.03 vs aged; ‡Pϭ0.01 vs agedϩMIF. C, Heart rate-LV pressure products of isolated young, aged, and AMPK KD hearts with or without MIF treatment; nϭ4 per group. *PϽ0.05 vs young; †Pϭ0.01 vs aged. D, Glucose uptake under baseline, ischemia, and reperfusion in hearts from young, aged, and AMPK KD mice supplemented with or without recombinant MIF ; nϭ5 per group. *PϽ0.05 vs baseline; †PϽ0.05 vs aged ischemia or reperfusion; ‡PϽ0.05 vs young ischemia or reperfusion. adult hearts. Hypoxia exposure resulted in depressed contractile function in both young and aged cardiomyocytes; ie, it reduced peak shortening ( Figure 6D ) and maximal velocity of shortening/relengthening (ϮdL/dt; Figure 6E and 6F) and prolonged time to 90% relengthening ( Figure 6H) . Nonetheless, the extent of hypoxic dysfunction was significantly accentuated in aged versus young cardiomyocytes. Additionally, hypoxia-triggered MIF release from young cardiomyocytes was significantly greater than that from aged cardiomyocytes ( Figure 6B ). To determine whether relative MIF deficiency in the aged heart was responsible for compromised cardiomyocyte mechanical function and AMPK activation during the hypoxic stress, recombinant murine MIF (10 ng/mL) was added to the media during hypoxic incubation. Exogenous MIF restored hypoxia-stimulated AMPK activation in aged cardiomyocytes ( Figure 6A ) and partially restored contractile function in response to hypoxia (Figure 6 C through 6H). In contrast, MIF had no effect on contractility indexes and AMPK activation in young cardiomyocytes. These data indicate that endogenous MIF maximally induces AMPK phosphorylation and contractility during hypoxia in young cardiomyocytes. However, in the aged and relatively MIF-deficient cardiomyocytes, exogenous MIF augmented contractility and AMPK activation during hypoxia.
MIF Increases AMPK Activity and Suppresses Ischemic Injury in the Aged Heart
To assess whether MIF supplementation decreases ischemic injury in the isolated perfused senescent heart, pretreatment for 20 minutes with MIF (10 ng/mL) followed by 20 minutes of global ischemia significantly increased ischemiastimulated AMPK phosphorylation ( Figure 7A ). Furthermore, recombinant MIF treatment decreased myocardial infarct size in these aged hearts ( Figure 7B ) and markedly increased recovery of function during the postischemic reperfusion period, as evidenced by the significantly improved heart rate-LV pressure product ( Figure 7C ). However, recombinant MIF did not affect myocardial infarct size and recovery of function during the postischemic reperfusion period for AMPK KD hearts ( Figure  7B and 7C) . Moreover, recombinant MIF enhanced glucose uptake during ischemia or reperfusion in aged hearts but failed to be effective in AMPK KD hearts ( Figure 7D ). We then used a genetic approach to address whether the upregulation of MIF in senescent hearts to levels observed in young hearts could likewise activate AMPK and preserve the cardiac response to ischemia. After intramyocardial injection of adenovirus-encoded MIF (5ϫ10 9 IFU/ mL) into the LV wall of aged hearts, the levels of cardiac MIF expression increased to those observed in young hearts ( Figure 7E ). Ischemic AMPK activity also was markedly increased in the adenovirus-encoded MIF treatment group compared with the 2 control groups ( Figure  7F ). After 20 minutes of coronary artery ligation and 4 hours of reperfusion, myocardial infarct size in the adenovirus-encoded MIF treated aged hearts was reduced compared with aged or control adenovirus (adenovirus-encoded LacZ) -injected hearts ( Figure 7G ). Therefore, an upregulation of cardiac MIF expression in aged hearts to levels seen in young adult hearts increased both AMPK activation and the tolerance of these hearts to ischemic injury.
Discussion
Elucidation and remediation of the mechanisms of agingassociated deterioration in I/R response may serve to improve clinical outcomes in the aging population. In this study, we demonstrate for the first time that endogenous MIF, an upstream activator cascade of AMPK, 20 is reduced in aged hearts. Specifically, impaired ischemia-induced AMPK activation was associated with an inability to augment glucose uptake during ischemia. Furthermore, impaired MIF-AMPK activation has important functional consequences in the reperfused postischemic senescence hearts, including reduced recovery of LV contractile function and larger infarcts. Although these observations provide evidence that cardiac MIF downregulation and a resulting impairment of ischemic AMPK activation play causative roles in the intolerance of the aged heart to ischemic injury, we cannot fully rule out the possibility that other factors such as mitochondrial dysfunction, reactive oxygen species formation, and impaired nitric oxide signaling 32 also may contribute to ischemic intolerance during aging.
The data in the present study support the conclusion that AMPK activity is significantly reduced in aged hearts, which leads to a dysregulation of glucose uptake during both ischemia and reperfusion in the aged hearts and likely accounts for reduced tolerance to ischemic stress in senescence. The observation was that there is no significant difference in the content of AMP and ATP at baseline and at the end of I/R, only lower ATP levels in the aged versus young hearts after ischemia ( Figure IIB of the online-only Data Supplement). However, the glycogen levels are different between young and aged hearts during both ischemia and reperfusion ( Figure IIC of the onlineonly Data Supplement). Therefore, these findings suggest that impaired ischemic AMPK activation of the aged heart leads to less ATP production, a greater shunting of glucose toward glycogen synthesis, and less glycolysis 18, 24 ( Figure II of the online-only Data Supplement). Therefore, a loss of ability to activate AMPK in the aged heart may result in impaired energy use, which contributes directly to postischemia contractile dysfunction. To further address these issues, the metabolic effects of impaired AMPK activation in the aged heart require further investigation.
We further show by complementary studies with recombinant or adenovirus-encoded MIF that increased AMPK activation in aged hearts effectively attenuates the impaired response to ischemic injury. Resveratrol reduces ischemic damage by several mechanisms such as reducing reactive oxygen species and activating nitric oxide, SIRT1, and Akt signaling pathways, 33 but it also activates AMPK as part of its cellular protective actions [33] [34] [35] [36] and reduces infarct size in aged hearts. Exogenously added MIF also restores the impaired AMPK signaling of aged hearts and modulates the substrate metabolism to adapt the stress conditions. Exogenous MIF did not influence infarct size in young hearts (data not shown), suggesting that endogenous MIF can maximally activate ischemic AMPK signaling in the young heart. There also is no significant difference in MIF secretion between young and aged hearts during nonstress conditions; however, an impairment in MIF secretion occurs with aging, leading to reduced AMPK activation and an increase in ischemic damage.
The precise mechanism of reduced MIF secretion in the aged heart is unknown. A recent report has identified the trafficking protein p115 as mediating MIF secretion 25 ; whether p115 expression or function is reduced in the aged heart would represent an avenue for further investigation. HIF plays an important role in the cellular response to hypoxia or ischemia. 37 It is also known that HIF-1␣ delays premature senescence through activation of MIF in murine embryonic fibroblasts. 30 An age-dependent decrease in HIF-1␣ expression was reported in brain, liver, and kidney of mice, 38 which supports the decreased ability of such aged tissues to respond to hypoxic stress. Rohrbach et al 39 have reported an aging-associated increase in prolyl-4-hydroxylase domain expression in mouse and human heart, which may account for a reduction in the activity of HIF-1␣ in the aged heart. The potentially protective role for HIF-1␣ in cellular senescence raises the possibility of a functional link between HIF-1␣ and MIF in explaining the sensitivity of the senescent heart to I/R stress ( Figure  III of the online-only Data Supplement).
Conclusions
An aging-associated decrease in the activity of the HIF-1␣-MIF axis in the heart may explain the impaired AMPK activation response to ischemia in the senescent heart. Pharmacological interventions that restore MIF signaling and AMPK activity in the senescent heart may be a novel means to limit cardiac damage caused by I/R in older cardiac patients.
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